Patient, disease, and transplant characteristics: reduced intensity regimens
| . | Donor type . | . | |
|---|---|---|---|
| Variable . | Haploidentical . | Unrelated . | P . |
| Number | 88 | 737 | |
| Age, y | <.001 | ||
| 21-50 | 19 (22%) | 41 (5%) | |
| 51-0 | 69 (78%) | 696 (95%) | |
| Sex, male | 51 (58%) | 415 (56%) | .77 |
| Performance score | .03 | ||
| 90-100 | 57 (65%) | 426 (58%) | |
| ≤80 | 23 (26%) | 300 (41%) | |
| Not reported | 8 (9%) | 11 (1%) | |
| Recipient CMV serostatus | .91 | ||
| Positive | 60 (68%) | 504 (68%) | |
| Negative | 28 (32%) | 229 (31%) | |
| Not reported | — | 4 (< 1%) | |
| Disease status at transplantation | <.001 | ||
| First complete remission | 43 (46%) | 447 (61%) | |
| Second complete remission | 31 (35%) | 128 (17%) | |
| Relapse | 14 (16%) | 162 (22%) | |
| Disease risk index | .11 | ||
| Low risk index | 4 (5%) | 13 (2%) | |
| Intermediate risk index | 68 (77%) | 542 (74%) | |
| High risk index | 16 (18%) | 182 (25%) | |
| Secondary AML | 20 (23%) | 182 (25%) | .68 |
| De novo AML | 68 (77%) | 555 (75%) | — |
| Cytogenetics* | .16 | ||
| Favorable | 4 (5%) | 23 (2%) | |
| Intermediate | 73 (83%) | 586 (80%) | |
| Adverse | 10 (11%) | 99 (13%) | |
| Not reported | 1 (1%) | 29 (4%) | |
| Conditioning regimen | N/A† | ||
| TBI + cyclophosphamide + fludarabine | 88 (100%) | 158 (21%) | |
| Busulfan/melphalan + fludarabine + ATG | __ | 291 (39%) | |
| Busulfan/melphalan + fludarabine | __ | 288 (39%) | |
| GVHD prophylaxis | N/A† | ||
| Tacrolimus/CSA + MMF | 85 (97%) | 315 (43%) | |
| Tacrolimus/CSA + MTX | — | 362 (49%) | |
| Tacrolimus/CSA + sirolimus | 3 (3%) | 60 (8%) | |
| Posttransplant cyclophosphamide | 88 (100%) | — | |
| Interval between diagnosis and transplant | .01 | ||
| ≤12 mo | 57 (65%) | 569 (77%) | |
| >12 mo | 31 (35%) | 168 (23%) | |
| Graft type | <.001 | ||
| BM | 77 (88%) | 80 (11%) | |
| Peripheral blood | 11 (13%) | 657 (89%) | |
| Transplant period | .83 | ||
| 2008-2010 | 48 (55%) | 404 (55%) | |
| 2011-2012 | 40 (45%) | 333 (45%) | |
| Follow up, median (range), mo | 39 (12-73) | 37 (7-75) | |
| . | Donor type . | . | |
|---|---|---|---|
| Variable . | Haploidentical . | Unrelated . | P . |
| Number | 88 | 737 | |
| Age, y | <.001 | ||
| 21-50 | 19 (22%) | 41 (5%) | |
| 51-0 | 69 (78%) | 696 (95%) | |
| Sex, male | 51 (58%) | 415 (56%) | .77 |
| Performance score | .03 | ||
| 90-100 | 57 (65%) | 426 (58%) | |
| ≤80 | 23 (26%) | 300 (41%) | |
| Not reported | 8 (9%) | 11 (1%) | |
| Recipient CMV serostatus | .91 | ||
| Positive | 60 (68%) | 504 (68%) | |
| Negative | 28 (32%) | 229 (31%) | |
| Not reported | — | 4 (< 1%) | |
| Disease status at transplantation | <.001 | ||
| First complete remission | 43 (46%) | 447 (61%) | |
| Second complete remission | 31 (35%) | 128 (17%) | |
| Relapse | 14 (16%) | 162 (22%) | |
| Disease risk index | .11 | ||
| Low risk index | 4 (5%) | 13 (2%) | |
| Intermediate risk index | 68 (77%) | 542 (74%) | |
| High risk index | 16 (18%) | 182 (25%) | |
| Secondary AML | 20 (23%) | 182 (25%) | .68 |
| De novo AML | 68 (77%) | 555 (75%) | — |
| Cytogenetics* | .16 | ||
| Favorable | 4 (5%) | 23 (2%) | |
| Intermediate | 73 (83%) | 586 (80%) | |
| Adverse | 10 (11%) | 99 (13%) | |
| Not reported | 1 (1%) | 29 (4%) | |
| Conditioning regimen | N/A† | ||
| TBI + cyclophosphamide + fludarabine | 88 (100%) | 158 (21%) | |
| Busulfan/melphalan + fludarabine + ATG | __ | 291 (39%) | |
| Busulfan/melphalan + fludarabine | __ | 288 (39%) | |
| GVHD prophylaxis | N/A† | ||
| Tacrolimus/CSA + MMF | 85 (97%) | 315 (43%) | |
| Tacrolimus/CSA + MTX | — | 362 (49%) | |
| Tacrolimus/CSA + sirolimus | 3 (3%) | 60 (8%) | |
| Posttransplant cyclophosphamide | 88 (100%) | — | |
| Interval between diagnosis and transplant | .01 | ||
| ≤12 mo | 57 (65%) | 569 (77%) | |
| >12 mo | 31 (35%) | 168 (23%) | |
| Graft type | <.001 | ||
| BM | 77 (88%) | 80 (11%) | |
| Peripheral blood | 11 (13%) | 657 (89%) | |
| Transplant period | .83 | ||
| 2008-2010 | 48 (55%) | 404 (55%) | |
| 2011-2012 | 40 (45%) | 333 (45%) | |
| Follow up, median (range), mo | 39 (12-73) | 37 (7-75) | |